Metabolic disorders associatedwith chronic hepatitis C: Impact of genotype and ethnicity

Liver International

Volumn 30, Issue 8, 2010, Pages 1131-1136

  Serst, Thomas ^a,b   Nkuize, Marcel ^a   Moucari, Rami ^b   Van Gossum, Marc ^a   Reynders, Marijke ^c   Scheen, Robert ^c   Vertongen, Françoise ^a   Buset, Michel ^a   Mulkay, Jean Pierre ^a   Marcellin, Patrick ^b  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b BEAUJON HOSPITAL   (France)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Chronic hepatitis C; Ethnicity; Genotype; Insulin resistance

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; AFRICAN AMERICAN; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CAUCASIAN; DEMOGRAPHY; DISEASE ASSOCIATION; ETHNICITY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; OBESITY; PREVALENCE; TRIACYLGLYCEROL BLOOD LEVEL; ANALYSIS OF VARIANCE; ARAB; BELGIUM; BLOOD PRESSURE; ETHNOLOGY; GENETICS; HEPATITIS C VIRUS; MIDDLE AGED; NEGRO;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANALYSIS OF VARIANCE; ARABS; BELGIUM; BLOOD PRESSURE; BODY MASS INDEX; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC DISEASES; MIDDLE AGED;

EID: 79951635297     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02291.x     Document Type: Article

References (34)

1. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007; 46: 37-47.
2. Castera L. Steatosis, insulin resistance and fibrosis progression in chronic hepatitis C. Minerva Gastroenterol Dietol 2006; 52: 125-34.
3. Fartoux L, Poujol-Robert A, Guechot J, et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-8.
4. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27: 2444-9.
5. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation 2005; 112: 2735-52.
6. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003; 125: 1695-704.
7. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21: 1135-9.
8. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328-33.
9. Zein NN, Abdulkarim AS, Wiesner RH, Egan KS, Persing DH. Prevalence of diabetes mellitus in patients with endstage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol 2000; 32: 209-17.
10. Harrison SA. Correlation between insulin resistance and hepatitis C viral load. Hepatology 2006; 43: 1168-9; 1168; author reply.
11. Svegliati-Baroni G, Bugianesi E, Bouserhal T, et al. Postload insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in nonalcoholic fatty liver disease. Gut 2007; 56: 1296-301.
12. Petta S, Camma C, Di Marco V, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 2008; 103: 1136-44.
13. Hanouneh IA, Feldstein AE, Lopez R, et al. Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2008; 6: 584-9.
14. Tsochatzis E, Papatheodoridis GV, Manesis EK, et al. Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008; 27: 80-9.
15. Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly relatedto intrahepatic triglyceride content in obese subjects. Gastroenterology 2008; 134: 1369-75.
16. Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Hepatology 2001; 33: 1554.
17. Lecube A, Hernandez C, Genesca J, Simo R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care 2006; 29: 1096-101.
18. Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008; 48: 28-34.
19. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-23.
20. Torres DM, Harrison SA. Insulin resistance in chronic hepatitis C, genotypes 1 and 4: the unfortunate reality. Hepatology 2008; 47: 2137-9.
21. Keane J, Meier JL, Noth RH, Swislocki AL. Computer-based screening of veterans for metabolic syndrome. Metab Syndr Relat Disord 2009; 7: 557-61.
22. Conjeevaram HS, Kleiner DE, Everhart JE, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007; 45: 80-7.
23. Roulot D, Bourcier V, Grando V, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007; 14: 460-7.
24. Morice Y, Roulot D, Grando V, et al. Phylogenetic analyses confirm the high prevalence of hepatitis C virus (HCV) type 4 in the Seine-Saint-Denis district (France) and indicate seven different HCV-4 subtypes linked to two different epidemiological patterns. J Gen Virol 2001; 82: 1001-12.
25. Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002; 97: 700-6.
26. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265-71.
27. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003; 37: 1343-50.
28. Delgado-Borrego A, Liu YS, Jordan SH, et al. Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCVand insulin resistance. Liver Transpl 2008; 14: 193-201.
29. Muzzi A, Leandro G, Rubbia-Brandt L, et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005; 42: 41-6.
30. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-8.
31. Negro F, Sanyal AJ. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int 2009; 29(Suppl. 2): 26-37.
32. Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int 2009; 29(Suppl. 2): 13-25.
33. Pattullo V, Heathcote J. Hepatitis C and diabetes: one treatment for two diseases? Liver Int 2009; 30: 356-64.
34. Harris RA, Sugimoto K, Kaplan DE, et al. Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans. Hepatology 2008; 48: 70-9. Liver